Certain disease states are characterized by disturbances in production, accumulation or clearance of protein. In Alzheimer disease, accumulation of amyloid-b (Ab) in the brain and disease-causing mutations in amyloid precursor protein or in enzymes that produce Ab indicate dysregulation of production or clearance of Ab. Whether dysregulation of Ab synthesis or clearance causes the most common form of Alzheimer disease (sporadic, 499% of cases), however, is not known. Here, we describe a method to determine the production and clearance rates of proteins within the human central nervous system (CNS). We report the first measurements of the fractional production and clearance rates of Ab in vivo in the human CNS to be 7.6% per hour and 8.3% per hour, respectively. This method may be used to search for novel biomarkers of disease, to assess underlying differences in protein metabolism that contribute to disease and to evaluate treatments in terms of their pharmacodynamic effects on proposed diseasecausing pathways.
Protein production and clearance are important parameters that are tightly regulated and reflect normal physiology as well as disease states [1] [2] [3] [4] . Previous studies of protein metabolism in humans have focused on whole-body or peripheral-body proteins, but not on proteins produced in the CNS. A technique to measure specific protein metabolism in the CNS could provide important insights into CNS protein physiology in health and disease. Certain disease states are characterized by disturbances in protein production, accumulation or clearance. In the CNS, disturbances in metabolism of proteins such as the prion protein 5 , alpha-synuclein 6 , tau 7 or Ab 8 can contribute to and, in some cases, cause neurodegenerative diseases such as Creuzfeldt-Jakob disease, Parkinson disease, frontotemporal dementia or Alzheimer disease, respectively.
Biochemical, genetic and animal model evidence implicates Ab as a pathogenic peptide in Alzheimer disease. The neuropathologic and neurochemical hallmarks of Alzheimer disease include synaptic loss and selective neuronal death, a decrease in certain neurotransmitters and the presence of abnormal proteinaceous deposits in neurons (neurofibrillary tangles), in the cerebral vasculature (amyloid angiopathy) and in the extracellular space (diffuse and neuritic plaques). The main constituent of plaques is Ab, a peptide of 38-43 amino acids cleaved from the amyloid precursor protein (APP) 9, 10 . Throughout life, soluble Ab is secreted mostly by neurons but also other cell types. In late-onset Alzheimer disease, the total amount of Ab that accumulates in brain is B100-200-fold higher in homogenates from Alzheimer disease brains than from control brains 11 . Disturbance of Ab production can lead to rare forms of Alzheimer disease in humans. Mutations in three different genes (APP, PSEN1 and PSEN2), which cause early-onset autosomal dominant Alzheimer disease, all result in overproduction of total Ab or Ab 42 (ref. 9). In Down syndrome, three copies of APP result in increased production of Ab, and 100% of individuals with Down syndrome develop Alzheimer disease pathology by age 35 (ref. 12) . In late-onset Alzheimer disease (B99% of cases), however, there is not strong evidence for overproduction of Ab. Therefore, the underlying cause of deposition of Ab (increased production versus decreased clearance) is not known for most cases of Alzheimer disease.
No methods were previously available to quantify protein synthesis or clearance rates in the human CNS. Such a method would be valuable to assess not only Ab synthesis and clearance rates in humans but also the metabolism of a variety other proteins relevant to diseases of the CNS. To address crucial questions about underlying pathogenesis of Alzheimer disease and Ab metabolism, we developed a method for quantifying the fractional synthesis rate (FSR) and fractional clearance rate (FCR) of Ab in vivo in the human CNS. Our results indicate that by administering a stable isotope-labeled amino acid ( 13 C 6 -leucine), sampling cerebrospinal fluid (CSF) and using high-resolution tandem mass spectrometry to quantify labeled Ab, reproducible rates of Ab synthesis and clearance can be quantified in humans.
RESULTS

In vivo labeling and quantification of Ab
To determine whether labeled Ab (Fig. 1) could be produced and detected in vivo in a human, one individual underwent a 24-h infusion of labeled leucine followed by a lumbar puncture to obtain CSF. We immunoprecipitated Ab from the CSF sample with the Ab-specific antibody m266, digested it with trypsin and analyzed it using liquid chromatography-mass spectrometry (LC-MS). The m266 antibody is directed against the central domain of Ab and binds to all Ab species containing amino acids 13-28. The results showed that unlabeled and labeled Ab could be detected and measured in human CSF (Fig. 2) .
We conducted a pharmacokinetic study to optimize the labeling and sampling times, so that detectable 13 C 6 -leucine labeling of Ab was achieved and maintained for an adequate period of time that permitted us to use steady-state equations to calculate Ab synthesis and clearance rates. We tested a range of 13 C 6 -leucine intravenous infusion dosages (1.8-2.5 mg/kg/h), durations (6, 9 or 12 h) and CSF or blood sampling times (sampling at 12-36 h; Table 1 ). We found that labeled Ab could be reliably quantified after 9 or 12 h of infusion of the label but not after 6 h of infusion of the label. The synthesis portion of the labeling curve could be determined in the first 12 h of sampling; however, the clearance portion of the labeling curve could only be determined with 36 h of sampling. Based on these results, we defined optimal labeling parameters for Ab to be 9 h of intravenous infusion of the label and 36 h of sample collection. These parameters allowed for assessment of both the FSR and FCR portions of the labeling curve.
In vivo labeling protocol For the last three individuals, we administered 13 C 6 -labeled leucine with an initial bolus of 2 mg/kg over 10 min to reach a steady state of labeled leucine, followed by 9 h of continuous intravenous infusion at a rate of 2 mg/kg/h. We sampled blood and CSF for 36 h in the last three individuals. We took serial 12-ml blood samples and 6-ml CSF samples at 1-or 2-h time intervals (Fig. 3a) . CSF has a production rate of B20 ml/h 13 in a normal-sized adult and replenishes itself throughout the procedure. Over a 36-h study, the total amounts of blood and CSF collected were 312 ml and 216 ml, respectively.
There were a total of ten individuals enrolled in the study, with eight completing the predefined protocols; we stopped two studies before completion because of postlumbar puncture headache associated with the study. Two of the eight completed studies had a 6-h labeled leucine infusion, and labeled Ab levels in these two individuals were too low to accurately measure and were not used for analysis. The findings from the remaining six studies are reported here.
Quantification of labeled leucine
We analyzed plasma and CSF samples to determine the amount of labeled leucine present in each fluid (Fig. 3b) . We quantified the labeled-to-unlabeled leucine ratios for plasma and CSF 13 C 6 -leucine using capillary gas chromatography-mass spectrometry (GC-MS) 14 , which is more suitable than LC-MS for analysis of low-mass amino acids. Within 1 h, the 13 C 6 -leucine reached steadystate levels in both plasma and CSF of 14% and 10%, respectively. This confirmed that leucine is rapidly transported across the blood-brain barrier through known neutral amino acid-transporter systems 15 .
Dynamics of labeled Ab
For each sample of CSF collected, we determined the labeled-to-unlabeled ratio of Ab by immunoprecipitation-tandem mass spectrometry (MS/MS) as described above. The number of MS/MS ions from labeled Ab* [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] was divided by the number of MS/MS ions from unlabeled Ab [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] to produce a ratio of labeled Ab to unlabeled Ab. The mean labeled Ab ratio and standard error (n ¼ 6) of each time point are shown in Figure 3c . There was no measurable labeled Ab for the first 4 h, followed by an increase from 5 to 13 h. There was no significant change from 13 to 24 h. The labeled Ab decreased from 24 to 36 h.
Calculation of FSR and FCR
We calculated FSR using the standard formula 16 :
Where (E t2 -E t1 ) Ab /(t 2 -t 1 ) is defined as the slope of the line during labeling, and Precursor E is the ratio of labeled leucine to unlabeled. FSR, in percent per hour, was operationally defined as the slope of the linear regression from 5 to 14 h divided by the average of CSF 13 C 6 -labeled leucine level during infusion (Fig. 4a-c) . For example, a FSR of 7.6% per hour means that 7.6% of total Ab is produced each hour. We calculated FCR by fitting the slope of the natural logarithm of the clearance portion of the labeled Ab curve.
We operationally defined this as the natural log of the labeled Ab from 24 to 36 h (Fig. 4d-f) . For example, a FCR of 8.3% per hour means that 8.3% of total Ab is cleared each hour. The average FSR of Ab for these six healthy young individuals was 7.6% per hour, and the average FCR was 8.3% per hour (Fig. 4g) . These values were not statistically different from each other.
DISCUSSION
We report a new method to determine the production and clearance rates of proteins present in the human CNS. The technique offers an accurate and reproducible way to determine the labeled amount of a protein that is in low picomolar abundance in human CSF. This technique may be adapted to measure proteins that are made in the CNS, present in the CSF or blood, and can be collected and measured by mass spectrometry as all proteins are labeled simultaneously. The method may be used to determine changes that may be present during a disease state (for example, Alzheimer disease), to find possible biomarkers and to test proposed disease-modifying therapies. This general approach may also be applied to other macromolecules produced in the CNS, including lipids, carbohydrates and inflammatory markers by infusing a labeled precursor that crosses the bloodbrain barrier and isolating the labeled and unlabeled products. In addition, the method may offer information on the compartmentalization of proteins if labeled species are measured in separate compartments such as blood and CSF. Several earlier studies have shown that some plasma Ab can enter the CNS [17] [18] [19] , although the percentage of CSF Ab that is derived from In one intravenous line, we infused 13 C 6 -labeled leucine at a rate of 1.8-2.5 mg/kg/h for 9 or 12 h, after an initial bolus of 2 mg/kg. We obtained 12 ml of plasma through the other intravenous line every hour for the first 16 h and every other hour thereafter, as depicted. We obtained 6 ml of CSF through the lumbar catheter every hour. (b) Labeled leucine in CSF and blood from an individual during a 36-h study. Labeled leucine in the CSF and plasma reaches a near steady-state level within an hour after we gave the initial bolus of 2 mg/kg. There was an exponential decay in labeled leucine levels after the infusion of leucine into the bloodstream was stopped at 9 h. The plasma labeled leucine is B4% higher than the CSF labeled leucine during infusion. (c) Average labeled CSF Ab over 36 h from six individuals. We averaged the labeled Ab curves and the mean for each time point is shown ± s.e.m. Each participant underwent labeling for 9 or 12 h, whereas sampling occurred hourly from 0 to 12, 24 or 36 h. There is no detectable incorporation of label in the first 4 h. This is followed by an increase in percent labeled Ab, which plateaus near steady-state levels of labeled leucine (B10%), before decreasing over the last 12 h of the study. We tested a range of labeling dosages, durations and sampling times. A labeling duration of 9 h and a sampling duration of 36 h allowed for calculation of FSR and FCR.
peripheral versus CNS sources has not been directly measured. The concentration of Ab in human brain and CSF is 50-100 times higher than in plasma 20 , and from g-secretase inhibitor studies, it seems that Ab generated in the CNS contributes to most Ab found in the CSF. For example, inhibition of Ab production outside the CNS can decrease plasma Ab by as much as 50% with no detectable change in brain or CSF Ab 21, 22 . Measurements of the FSR and FCR of Ab in the CSF are likely to be measurements of Ab produced largely in the CNS, but may also reflect a small amount of Ab synthesized in the periphery. There exist established stable isotope-tracer methods for quantifying synthesis and clearance rates of abundant (microgram to milligram) quantities of peripheral (liver, muscle lung) human proteins, for example, albumin, apolipoprotein B, myosin and surfactant 4, 23, 24 . In general, these methods measure the abundance of the labeled and unlabeled proteins by using GC-MS of the derivitized amino acids. This approach is sensitive and accurate but requires relatively large amounts of purified protein and, as such, is not ideal for lowabundance proteins like Ab (present in low picomolar quantities). Recent advances in electrospray ionization mass spectrometers and MS/MS quantification provided the opportunity to further refine this approach so that sensitive, accurate and reproducible quantification of stable isotope labeling (±1%) in very-low-abundance proteins and peptides (picomolar) can be achieved. Our method exploits this technology to quantify in vivo incorporation of 13 C into Ab that has been immunoprecipitated from human CSF, digested with trypsin and used to quantify in vivo Ab protein synthesis and clearance rates.
During labeling, all proteins that are being produced are labeled simultaneously, which offers the possibility of measuring multiple protein production and clearance rates on the same sample. In addition, other isotopomer labels may be used, including other amino acids, simple carbohydrates or acetate to determine kinetics of proteins, carbohydrates or fatty acids, respectively.
We chose to use a steady-state labeling infusion; however, others have used a bolus-chase design peripherally 25 . As shown, curves depicting plasma and CSF labeled leucine were similar in shape, with both having a steady state of labeling for 9 h and rapid clearance of the label. Plasma leucine was labeled at 14% whereas CSF leucine was labeled at 10% during infusion of the label. In individuals in our study, levels of labeled Ab in the CSF approached levels of labeled leucine in the CSF (average, 8.9% and 11.2%, respectively), suggesting that labeled leucine in the CSF more closely reflects the labeled leucine precursor in the brain compared to plasma. We chose to use the plateau of labeled leucine in the CSF in our estimates of FSR, as levels of labeled leucine in the brain are likely to be closer to levels in CSF than plasma.
Our results indicate Ab is rapidly produced and cleared from the CNS in humans. To our knowledge, this represents the first estimate of the synthesis and clearance rate of a protein produced in the human CNS. The clearance rate of Ab in humans measured by this technique is similar to, but slower than, that measured in mouse brain by in vivo microdialysis 26 . Possible reasons for the differences include species difference in metabolism rate or the measurement technique.
In our current experiments, we have determined the synthesis and clearance of all Ab species, as we immunoprecipitated Ab with an antibody to the central domain of the molecule. To measure synthesis and clearance of specific Ab species, such as Ab 40 or Ab 42 , we would need to perform an immunoprecipitation of these species with C-terminal-specific antibodies. This method may be used to determine changes in the underlying pathophysiology of Alzheimer disease or as a way to test new therapeutics (for example, b-or g-secretase inhibitors) by measuring the pharmacodynamic effect of the therapy on Ab synthesis or clearance in humans.
METHODS
Human studies. All human studies were approved by the Washington University Human Studies Committee and the General Clinical Research Center (GCRC) Advisory Committee. Informed consent was obtained from all participants. All participants were screened to be in good general health and without neurologic disease. Seven men and three women (between 23 and 45 years) participated. Each individual was admitted to the GCRC at 07:00 after an overnight fast from 20:00 the preceding evening. The GCRC Research Kitchen provided meals (60% carbohydrate, 20% fat, 20% protein, low-leucine diet during labeled leucine infusion) at 09:00, 13:00 and 18:00. Individuals had free access to water. All food and water consumption was recorded during the admission by nursing staff and the GCRC kitchen. We placed one intravenous catheter in an antecubital vein and used it to administer the stable isotopelabeled leucine solution. We placed a second intravenous catheter in the contralateral antecubital vein to obtain blood samples. We inserted a subarachnoid catheter at the L3-L4 interspace using a Touhy needle, so that CSF could be sampled without performing multiple lumbar punctures 27 . The intravenous catheters were put in place by trained registered nurses and the lumbar catheter by trained physicians with experience in lumbar puncture. We obtained blood samples hourly, unless the study was 36 h, in which case blood was obtained hourly for the first 16 h and every other hour thereafter. We obtained CSF samples hourly throughout the study. We encouraged the participants to stay in bed except to use the restroom. We dissolved 13 C 6 -leucine in medical-grade normal saline and then filtered it through a 0.22-mm filter the day before each study. We infused the labeled leucine intravenously using a medical intravenous pump at a rate of 1.8-2.5 mg/kg/h.
We obtained 13 C 6 -leucine (CLM-2262) from Cambridge Isotope Laboratories. M266 antibody was generously provided by Eli Lilly 28 . We obtained CNBr-activated Sepharose 4B beads from Amersham Biosciences. We obtained formic acid (98%) and ammonium bicarbonate (ultra 499.5%) from Fluka and sequence grade-modified trypsin from Promega.
Ab immunoprecipitation. We prepared antibody beads by covalently binding m266 antibody to CNBr Sepharose beads per the manufacturer's protocol at a concentration of 10 mg/ml m266 antibody. We stored the antibody beads at 4 1C in a 50% slurry of PBS 0.02% azide.
The immunoprecipitation mixture consisted of 250 ml 5Â RIPA, 12.5 ml 100Â protease inhibitors and 30 ml antibody-bead slurry added to 1 ml of sample in an Eppendorf tube, which we rotated overnight at 4 1C. We rinsed the beads once with 1Â RIPA and twice with 25 mM ammonium bicarbonate. They were aspirated dry after the final rinse and we eluted Ab off the antibodybead complex using 30 ml pure formic acid. After centrifuging the beads again, we transferred the formic acid supernatant to a new Eppendorf tube for speedvacuum drying. We evaporated the formic acid in a Savant speed-vac (model AES2010) for 15 min at low rate (ambient temperature, 20 1C) temperature with radiant cover and full vacuum, followed by 30 min at medium rate (43 1C) with radiant cover and full vacuum. We reconstituted the sample in 5 ml acetonitrile and 20 ml 25 mM ammonium bicarbonate, pH 8.0. We digested the sample with 400 ng sequence-grade trypsin and incubated it at 37 1C for 16 h.
Liquid chromatography-mass spectrometry. We interfaced a Waters capillary liquid chromatography system with autoinjector to a Thermo-Finnigan LCQ-DECA equipped with an electrospray ionization source (LC-ESI-MS/MS). We injected a 5-ml aliquot of each sample onto a Vydac C-18 capillary column (0.3 Â 150 mm). In positive-ion scanning mode, LC-ESI-MS/MS analysis of trypsin-digested synthetic and immunoprecipitated Ab yielded the expected parent ions at a mass of 1,325.2 for Ab 17-28 and 1,331.2 for 13 C 6 -leucine labeled Ab [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] . To obtain amino acid sequence and abundance data, we subjected these parent ions to collision-induced dissociation (28%), and MS/MS analysis of their doubly charged species ([M+2H] +2 ; m/z 663.6 and 666.6) were scanned in selected reaction monitoring mode, so that the y-and b-series ions generated were used for isotope ratio quantification.
Calculation of labeled ratio. We calculated percent labeled Ab as the ratio of the number of labeled MS/MS ions from Ab* [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] divided by the number of unlabeled MS/MS ions from Ab [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] . We used a custom Microsoft Excel spreadsheet with macros to calculate the Ab ratio as the tracer-to-tracee ratio (TTR) of Ab 17-28 using the formula:
A detailed description of the mass spectrometry methods and quantification of labeled versus unlabeled peptides is in preparation (R.B., D.M.H. & K.E.Y., unpublished data).
